Cuprina Holdings (Cayman) Limited (Class A) (CUPR) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Cuprina Holdings (Cayman) Limited (Class A) (NASDAQ: CUPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $1.84 (+3.96% 1D, market cap $13.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CUPR ranks #972 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), CUPR carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of -1.3%, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and HSCS (HeartSciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M). Among the 5-stock peer group, CUPR leads on earnings multiple (N/A) while CUPR leads on capital efficiency (-35.0% ROIC).
Per CUPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001995704), Cuprina Holdings (Cayman) Limited (Class A) generated $38.8K in revenue (+9.2% YoY), -$3.6M in net income, and -$7.1M in free cash flow against $6.6M in total assets and $98.1K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 41.1 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CUPR currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.26) and Max Pain ($1.93) forces dealer call-delta covering toward $15.54.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cuprina Holdings (Cayman) Limited (Class A) (CUPR) surged +3.96% to $1.84, trading at 3% of its 52-week range ($1.45 – $14.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Acquiring 100% of East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for approximately S$4.0 million (approximately US$3.1 million)Target Group generated FY2025 unaudited revenue of approximately S$9.1 m
SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, med
SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, med
SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, med
Cuprina Holdings said its medicinal larvae product, MEDIFLY Maggots, has been approved by the FDA to treat non-healing injuries, such as diabetic foot ulcers.
SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical
SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medi
SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medic
SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medic
VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / SUPER COPPER CORP. (CSE:CUPR)(OTCQB:CUPPF)(FSE:N60) ("Super Copper" or the "Company"), is pleased to announce that Zachary Dolesky, Founder and Chief Executive Officer,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CUPR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CUPR. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Cuprina Holdings (Cayman) Limited (Class A) (CUPR) ranks #972 by composite RQD confidence (21/100, grade E) and #862 by equity capitalization ($13.5M). Within this direct 5-issuer industry benchmark cohort, CUPR leads on earnings valuation at N/A trailing P/E, while CUPR leads on capital efficiency and profitability with -35.0% ROIC and -1.3% gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with CUPR at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CUPR
ACTIVE
Cuprina Holdings (Cayman) Limited (Class A) | E | 21/100 | — | -1.3% | -35.0% | +3.96% | $13.5M | Benchmark Subject |
| CLGN CollPlant Biotechnologies Ltd | D- | 41/100 | — | 64.8% | -35.0% | -1.33% | $11.9M | /clgn-vs-cupr → |
| HSCS HeartSciences Inc. | D- | 38/100 | — | 59.1% | -35.0% | -9.67% | $16.0M | /hscs-vs-cupr → |
| LFWD Lifeward Ltd. | E | 32/100 | — | 96.0% | -35.0% | +1.82% | $16.9M | /lfwd-vs-cupr → |
| RGNT Regentis Biomaterials Ltd. | E | 31/100 | — | — | -35.0% | 0.00% | $9.6M | /rgnt-vs-cupr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cuprina Holdings (Cayman) Limited (Class A) (CUPR) reported GAAP revenue of $38.8K (+9.2% vs. FY2024 revenue of $35.5K ) , GAAP net income of -$3.6M, operating cash flow of -$7.1M, and free cash flow of -$7.1M (-672.8% YoY). On the balance sheet, CUPR closed FY2025 with $6.6M in total assets against $98.1K in total debt (Altman Z-Score: 0.36, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $38.8K | -$3.6M | -$7.1M | -$7.1M | $6.6M | $98.1K |
| FY2024 (FY) | 2024-12-31 | $35.5K | -$1.1M | -$908.6K | -$924.7K | $1.3M | $120.4K |
As of 2026-11-03, Cuprina Holdings (Cayman) Limited (Class A) (NASDAQ: CUPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $1.84 (+3.96% 1D, market cap $13.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CUPR ranks #972 in composite RQD confidence.
Within the Health Care sector (Industrial Specialties), CUPR carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of -1.3%, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and HSCS (HeartSciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M). Among the 5-stock peer group, CUPR leads on earnings multiple (N/A) while CUPR leads on capital efficiency (-35.0% ROIC).
Per CUPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001995704), Cuprina Holdings (Cayman) Limited (Class A) generated $38.8K in revenue (+9.2% YoY), -$3.6M in net income, and -$7.1M in free cash flow against $6.6M in total assets and $98.1K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
CUPR last traded at $1.84 (+3.96% on volume of 281,262 shares), positioning the stock -18.58% below its 50-day simple moving average ($2.26) and -38.67% below its 200-day simple moving average ($3.00). Across its 52-week range of $1.45 to $14.80, CUPR sits at the 2.9% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.61 to $2.07).
Cuprina Holdings (Cayman) Limited (Class A) (CUPR) earns a live Roarable RQD composite score of 21/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.84 (+3.96% 1D, market capitalization $13.5M).
Limited (Class A) trades on NASDAQ under ticker CUPR and is classified in the Health Care sector and Industrial Specialties industry. Per the financials, reported revenue is — in both FY 2025 and FY 2024. — for product lines, customer base, or revenue model.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cuprina Holdings (Cayman) Limited (Class A) (CUPR) reported $38.8K in annual revenue (up from $35.5K in FY2024, +9.2% YoY) and -$3.6M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($35.5K revenue, -$1.1M net income) through FY2025, CUPR scaled operating cash flow to -$7.1M and free cash flow to -$7.1M, backed by $6.6M in total assets against $98.1K in total debt.
— for upstream or downstream dependencies, sector correlations, or bottlenecks.
Real-time company headlines, analyst actions, and sector developments for Cuprina Holdings (Cayman) Limited (Class A) (CUPR) • Click "Debate This Headline" to argue it in the Roar Pit below
Acquiring 100% of East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for approximately S$4.0 million (approximately US$3.1 million)Target Group generated FY2025 unaudited revenue of approximately S$9.1 m
SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, med
SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, med
SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, med
Cuprina Holdings said its medicinal larvae product, MEDIFLY Maggots, has been approved by the FDA to treat non-healing injuries, such as diabetic foot ulcers.
SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical
SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medi
SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medic
The street is overcomplicating Cuprina Holdings (Cayman) Limited (Class A) (CUPR). Cash on the balance sheet rose to $2.4M in FY 2025 with Debt/Equity at 0.02 per the RQD rating.. With an RQD score of 21/100 (E) and Forensic Balance Sheet at 2/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.91.
@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Industrial Specialties. If gross margin (-1.3%) holds, EPS grows into the multiple faster than bears think.
Careful chasing CUPR at $1.77. ROIC of -35% and an Altman Z-Score of 0.36 signal weak returns and forensic distress.. Gross margin is -1.3%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.36 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: